THE EFFECT OF BICYCLOL ON THE STATE OF THE CONNECTIVE TISSUE COMPONENTS OF THE LIVER EXTRACELLULAR MATRIX IN THE COMPLEX THERAPY OF NON-ALCOHOLIC STEATOHEPATITIS WITH LIVER FIBROSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Authors

  • Zorіana Ya. Kotsіubiіchuk Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine
  • Oksana S. Khukhlina Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine
  • Aliona A. Antonіv Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine
  • Oleksandra I. Roshchuk Department of Dental Orthopedics, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine
  • Olga Ye. Mandryk Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine
  • Oleksandra V. Garvasіuk Department of Pathological Anatomy, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine

DOI:

https://doi.org/10.21272/eumj.2021;9(4):432-440

Keywords:

non-alcoholic steatohepatitis, type 2 diabetes mellitus, diabetic kidney disease, liver steatosis, liver fibrosis, Вicyclol

Abstract

The aim of the research was to determine the probable effect of metformin, rosuvastatin and bicyclol on markers of hepatocyte cytolysis in patients with nonalcoholic steatohepatitis and diabetes mellitus type 2 with diabetic kidney disease, the degree of hepatocyte steatosis and stage of liver fibrosis, as well as the content of extracellular protein and carbohydrate components in the blood tissues that are markers of the intensity of liver fibrosis and the progression of non-alcoholic steatohepatitis.

Materials and methods. Studу of changes in the course of treatment of 60 patients with nonalcoholic steatohepatitis with type 2 diabetes mellitus and stage I–IV diabetic kidney disease was conducted, among whom 48 patients were diagnosed with mild non-alcoholic steatohepatitis and 12 – with moderate non-alcoholic steatohepatitis. A comorbid disease, i.e. type 2 diabetes mellitus of moderate severity, was registered in 100% of patients with nonalcoholic steatohepatitis: among them, 15 people had diabetes in the compensatory stage, 45 people – in the subcompensated stage. All patients with nonalcoholic steatohepatitis and type 2 diabetes had comorbid diabetic kidney disease, including 21 cases of stage I–II diabetic kidney disease, 20 cases of stage III diabetic kidney disease, and 19 patients with stage IV diabetic kidney disease.

Results. Analysis of the results of extracellular matrix connective tissue metabolism in the blood of patients with non-alcoholic steatohepatitis on the background of type 2 diabetes mellitus and diabetic kidney disease indicated that the inflammatory and dysmetabolic process contributed to a significant imbalance of connective tissue components. In particular, activation of anabolic collagen was shown on the basis of an increase in blood protein-bound oxyproline by 2 times (p < 0.05), as well as a decrease in the intensity of collagen catabolism – based on a decrease in blood free oxyproline by 1.4 times (p < 0.05), which probably occurred due to inhibition of collagenolytic activity of blood plasma (by 1.4 times, p < 0.05). That is, activated processes of collagen synthesis were accompanied by inhibition of its degradation and accumulation in the extracellular matrix. We also found a significant increase in the blood content of hexosamines by 1.5 times (p < 0.05) and accelerated degradation of carbohydrate-protein components of the matrix (with an increase in the content of unbound fucose by 2.6 times, (p < 0.05)).

Conclusions. The combination therapy with metformin, rosuvastatin in combination with Вicyclol in individuals with comorbid nonalcoholic steatohepatitis, type 2 diabetes mellitus and diabetic kidney disease for 3 months helped to eliminate the syndrome of cytolysis of hepatocytes, a significant reduction liver fibrosis intensity due to optimization of spectrum of connective tissue components of the extracellular matrix in the blood with a decrease in the content of markers of collagen anabolism, increase in the content of markers of collagen catabolism due to increased total collagenolytic activity of blood plasma, decrease in the content of hexosamines and carbohydrate protein markers.

Downloads

Download data is not yet available.

Author Biographies

Zorіana Ya. Kotsіubiіchuk, Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine

асистент кафедри внутрішньої медицини, клінічної фармакології та професійних хвороб, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002

Oksana S. Khukhlina, Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine

д-р. мед. наук, професор, завідувач кафедри внутрішньої медицини, клінічної фармакології та професійних хвороб, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002

Aliona A. Antonіv, Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine

док. мед. наук, професор кафедри внутрішньої медицини, клінічної фармакології та професійних хвороб, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002

Oleksandra I. Roshchuk, Department of Dental Orthopedics, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine

к-т мед. наук, асистент кафедри ортопедичної стоматології, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002

Olga Ye. Mandryk, Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine

к-т мед. наук, асистент кафедри внутрішньої медицини, клінічної фармакології та професійних хвороб, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002

Oleksandra V. Garvasіuk, Department of Pathological Anatomy, Higher Educational Establishment “Bukovinian State Medical University”, Chernivtsi, Ukraine

к-т мед. наук, асистент кафедри патологічної анатомії, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002

References

Babak OYа, Kolesnikova YeV, Sytnik KA. The effect of bicyclol on the dynamics of cytolytic syndrome in patients with nonalcoholic fatty liver disease. Suchasna gastroyentrologíya. 2013;4(72):18-22.

Ivashkin VT, Mayevskaya MV, Zharkova MS i dr. Algorithm and diagnostics of treatment in gastroenterology M.: MEDpress-inform; 2016. 176 s. https://www.rsls.ru/files/news/Present2208.pdf

Pirogova IYu, Yakovleva SV, Neuymina TV i dr. Efficacy and safety of bicyclol in nonalcoholic fatty liver disease: results of a cohort study. Ros. zhurnal gastroenterologii, gepatol, koloproktologii. 2018;28(4):66-75. https://doi.org/10.22416/1382-4376-2018-28-4-66-75.

Khukhlina OS, Antoniv AA, Mandryk OYe, Hrynyuk OYe. Non-alcoholic fatty liver disease and comorbid conditions: features of pathogenesis, clinic, diagnosis, treatment. Chernivtsi, 2017. 188 s.

Khukhlina OS, Antoniv AA, Kuzʹminsʹka OB. ta in. Intensity of fibrosis in the liver and patients with non-alcoholic steatohepatitis on the background of obesity I-II degrees and chronic kidney disease. Zdobutky klinichnoyi i eksperymentalʹnoyi medytsyny. 2018; (2 (34)): 147–151.

Khukhlina OS, Antoniv AA. Non-alcoholic fatty liver disease and chronic kidney disease: pathogenesis of mutual burden, clinical features, diagnosis, prognosis. Chernivtsi, 2019. 192р.

Antoniv АА. Changes in extracellular matrix components metabolismin patients with nonalcoholic steatohepatitis on the background of obesity and comorbidity with chronic kidney disease. Ukr. zhurnal medytsyny, biolohiyi ta sportu. 2018; 3 (7 (16)): 69–73.

Shang W, Feng Y, Li J et al. Effect of bicyclol tablets on drug induced liver injuries after kidney transplantation. Open Medicine. 2017;12(1):62–69. doi: 10.1515/med-2017-0012.

Radchenko OM, Khukhlina OS, Antoniv AA, Mandryk OYе, Hrynyuk OYе, Kotsіubiіchuk ZYа, Antofiychuk TM. Hepatoprotectors:. Monohrafiya. Za red. prof. Radchenko OM, Khukhlinoyi OS. Chernivtsi, 2021. 388 s.

Khukhlina OS, Antoniv AA, Mandryk OYе. Effect of glycyrrhizin in combination with glycine and methionine on the state of extracellular matrix components on the intensity of liver fibrosis in patients with non-alcoholic steatohepatitis in comorbidity with chronic kidney disease. Suchasna hastroenterolohiya. 2017. № 5 (97). S. 29–35. http://nbuv.gov.ua/UJRN/SGastro_2017_5_7.

Cui J, Li Z, Qian L et al. Reducing the oxidative stress mediates the cardioprotection of bicyclol against ischemia-reperfusion injury in rats. Journal of Zhejiang University Science B. 2013;14(6):487–495. doi: 10.1631/jzus.B1200263

Mayevskaya MV, Lunkov VD, Geyvandova NI et al. Bicyclol in the treatment of patients with chronic diffuse liver diseases. Meditsinskiy sovet - Medical Council. 2020; (15): 42-53.

Golubovskaya OA, Merkulova YuV, Nosal'skaya TN. Bicyclol. The mechanism of realization of clinical effect. Pharmacodynamics. Clinical pharmacology. Obzor mnogotsentrovykh klinicheskikh issledovaniy Farmakodinamika. Klinicheskaya farmakologiya. Obzor mnogotsentrovykh klinicheskikh issledovaniy. Kiyеv, 2015. 61s. http://bicyclol.com/wp-content/uploads/Bicyclol-Golubovskaya-O.A.pdf

Xie W, Shi G, Zhang H. et al. A randomized, multicentral, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int. 2012;6(2):441–448. doi: 10.1007/s12072-011-9294-7.

Zhang Y, Xie Y, Zhang Y et al. Hepatitis B patients exhibiting mild alanine aminotransferase elevation: A comparative analysis of treatment with and without Bicyclol tablets. Biomed Rep. 2016; 5(5):595–600. doi: 10.3892/br.2016.765.

Naqiong W, Liansheng W, Zhanying H et al. A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury. Med Sci Monit. 2017;23:5760–5766. doi: 10.12659/msm.904090

Wang Y, Nie H, Zhao X. et al. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer. 2016;16:742. doi: 10.1186/s12885-016-2767-2.

Downloads

How to Cite

Zorіana Ya. Kotsіubiіchuk, Oksana S. Khukhlina, Aliona A. Antonіv, Oleksandra I. Roshchuk, Olga Ye. Mandryk, & Oleksandra V. Garvasіuk. (2021). THE EFFECT OF BICYCLOL ON THE STATE OF THE CONNECTIVE TISSUE COMPONENTS OF THE LIVER EXTRACELLULAR MATRIX IN THE COMPLEX THERAPY OF NON-ALCOHOLIC STEATOHEPATITIS WITH LIVER FIBROSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eastern Ukrainian Medical Journal, 9(4), 432–440. https://doi.org/10.21272/eumj.2021;9(4):432-440